The Accelerated Access Review (AAR) officially launched on 23 March 2015 when its terms of reference and Chair were announced by the Government.
The Review will make recommendations to Government on reforms to accelerate access for NHS patients to innovative medicines and medical technologies. This is the widest ranging review of the environment for the industry since 2009/10 when an incoming government finalised and launched the Life Sciences Strategy and Innovation, Health and Wealth. As its scope covers the whole medicines lifecycle, it touches on all our members’ interests.
The Review published its interim report on 27 October 2015. Click here for the full ABPI comment. The AAR will deliver a final report by April 2016.
The ABPI has fully engaged with the Review and its advisers on behalf of our members. We have been working closely with the Review team to ensure that the views of the innovative medicines sector are taken on board.
This has involved, agreeing an industry secondee into the Review team, arranging a series of roundtable meetings between ABPI member companies and the Review workstream leads and champions, one on one meetings with senior members of the Review team and preparing the ABPI submission to the Review: ABPI Submission to the AAR.pdf.
The ABPI has now submitted its final comments to the AAR: ABPI AAR Final Submission 4 Jan 2016.pdf
Below is an overview of all of our work so far, as well as some information on our upcoming activities. If you have any specific queries, please contact Audrey Yvernault Director of Government and External Affairs on 0207 747 7136 or firstname.lastname@example.org.
To go to the Accelerated Access Review website, please click here.